The abstract is read at the publisher; the summary is JClub's.
In SETBP1D886N-mutant human HSPCs, the KMT2A–MENIN complex is a targetable dependency, and MEN1 deletion phenocopies KMT2A loss to suppress leukemogenic programs.
- Why it matters: SETBP1 mutations drive poor outcomes in high-risk myeloid malignancies, but the human HSPC epigenetic dependencies sustaining their HOX-linked transcriptional state are unclear.
- What they did: They mapped a 94-gene SETBP1 regulome using integrated transcriptional and chromatin profiling, then used CRISPR-Cas9 to test KMT2A complex components and applied KMT2A–MENIN inhibitors to block serial replating and target gene expression.
- The result: KMT2A–MENIN inhibition suppressed canonical SETBP1 targets, reduced H3K4me3 at leukemogenic loci, and impaired clonogenic growth across primary SETBP1-mutant leukemia patient samples while promoting myeloid differentiation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.